Voronoi, Inc. (KOSDAQ:310210)

South Korea flag South Korea · Delayed Price · Currency is KRW
287,000
+5,000 (1.77%)
Apr 10, 2026, 3:30 PM KST
Market Cap5.07T +115.4%
Revenue (ttm)7.51B
Net Income-42.71B
EPS-2,374.00
Shares Out17.99M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume76,297
Average Volume98,077
Open279,500
Previous Close282,000
Day's Range276,500 - 297,500
52-Week Range89,800 - 375,500
Beta1.76
RSI47.28
Earnings DateMay 8, 2026

About Voronoi

Voronoi, Inc. researches, develops, and discovers small molecule kinase inhibitors in South Korea. Its products pipeline includes VRN01, an oral leucine rich repeat kinase 2 inhibitor targeting glioblastoma multiforme to treat brain and pancreatic cancers; VRN07, VRN06, and VRN11 for the treatment of lung cancer; VRN08 and VRN10 to treat breast cancer; and VRN02 for the treatment of rheumatoid arthritis and atopic dermatitis. The company’s products pipeline also comprise VRN04-1 to treat autoimmune diseases; VRN04-2 for the treatment of multipl... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2015
Employees 140
Stock Exchange KOSDAQ
Ticker Symbol 310210
Full Company Profile

Financial Performance

Financial Statements